Neil Gregory Almstead, who serves as the Chief Technical Operations Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), executed a series of stock transactions on July 6 and 7, 2026. These activities involved the sale of common stock totaling approximately $4.1 million and the acquisition of common stock valued at roughly $1.8 million. All transactions were carried out under the framework of a pre-arranged Rule 10b5-1 trading plan that was adopted on November 11, 2025.
The sales activity took place while PTCT shares were trading at $88.57, a level near the stock's 52-week high of $89.80. This price point follows an 87% gain over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value.
Mr. Almstead sold a total of 46,774 shares of PTC Therapeutics common stock. These sales occurred at weighted average prices ranging from $85.00 to $89.75 per share, with specific transactions ranging from $85.28 to $89.44 per share. The aggregate value of these sales amounted to $4,093,481.
Concurrently, Mr. Almstead acquired a total of 46,774 shares of common stock. These acquisitions were primarily through the exercise of stock options at prices ranging from $38.10 to $39.42 per share. The total value of these acquired shares was $1,817,844. The stock options exercised were either currently exercisable or part of a grant from January 5, 2023, which vests over four years.
Following these transactions, Mr. Almstead directly holds 60,299 shares of common stock. His reported holdings also include 2,899 shares held indirectly by his spouse. Additionally, the reported holdings reflect 162 shares acquired under the company’s employee stock purchase plan for the period ended June 30, 2026.
For deeper insights into PTCT’s valuation and performance, investors can access the comprehensive Pro Research Report, one of 1,400+ available on InvestingPro, featuring expert analysis and 11 additional ProTips.
Key Points
- Executive Trading Activity: Chief Technical Operations Officer Neil Almstead sold $4.1 million and acquired $1.8 million in stock under a pre-arranged trading plan, maintaining a direct holding of 60,299 shares.
- Strong Financial Performance: PTC Therapeutics reported a strong earnings performance for the first quarter of 2026, beating analyst expectations with an earnings per share of -$0.03, compared to the forecasted -$0.46. The company also exceeded revenue projections, reporting $273 million against the anticipated $224.08 million.
- Analyst Upgrades: PTC Therapeutics has been the subject of several analyst upgrades. Jefferies upgraded the company’s stock rating to Buy from Hold, citing optimism about Sephience’s future revenue potential. Similarly, TD Cowen also upgraded PTC Therapeutics to Buy, highlighting the company’s operational improvements and successful product launch. BofA Securities reiterated its Buy rating, emphasizing the momentum of the Sephience launch and the company’s confidence in its global peak sales potential.
Risks and Uncertainties
- Valuation Concerns: According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, which may present risks for investors seeking entry points near the 52-week high.
- Market Volatility: The stock's recent 87% gain over the past year and its current trading near the 52-week high of $89.80 suggest potential volatility, which could impact the broader biotechnology and pharmaceutical sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Is PTCT undervalued—or a trap? Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what PTCT is really worth. Get instant clarity on PTCT—plus thousands of other stocks—before the opportunity disappears.
July Sale - 60% Off InvestingPro